Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2.
Bell JA, Davies ER, Brereton CJ, Vukmirovic M, Roberts JJW, Lunn K, Wickens L, Conforti F, Ridley RA, Ceccato J, Sayer LN, Johnston DA, Vallejo AF, Alzetani A, Jogai S, Marshall BG, Fabre A, Richeldi L, Monk PD, Skipp P, Kaminski N, Offer E, Wang Y, Davies DE, Jones MG. Bell JA, et al. Among authors: monk pd. Cell Rep Med. 2024 Sep 17;5(9):101695. doi: 10.1016/j.xcrm.2024.101695. Epub 2024 Aug 21. Cell Rep Med. 2024. PMID: 39173635 Free PMC article.
Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD.
Monk PD, Brookes JL, Tear VJ, Batten TN, Newall C, Mankowski M, Crooks MG, Singh D, Chaudhuri R, Leaker B, Lunn K, Reynolds S, Dudley S, Gabbay FJ, Holgate ST, Djukanovic R, Wilkinson TM. Monk PD, et al. Respir Res. 2024 May 29;25(1):228. doi: 10.1186/s12931-024-02854-7. Respir Res. 2024. PMID: 38811970 Free PMC article. Clinical Trial.
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W; ACTIV-2/A5401 Study Team. Jagannathan P, et al. Among authors: monk pd. EClinicalMedicine. 2023 Oct 6;65:102250. doi: 10.1016/j.eclinm.2023.102250. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37855026 Free PMC article.
Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study.
Monk PD, Brookes JL, Tear VJ, Batten TN, Mankowski M, Adzic-Vukicevic T, Crooks MG, Dosanjh DPS, Kraft M, Brightling CE, Gabbay FJ, Holgate ST, Djukanovic R, Wilkinson TMA. Monk PD, et al. ERJ Open Res. 2023 Mar 27;9(2):00605-2022. doi: 10.1183/23120541.00605-2022. eCollection 2023 Mar. ERJ Open Res. 2023. PMID: 36994453 Free PMC article.
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.
Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, Clark T, Djukanovic R, Wilkinson TMA; Inhaled Interferon Beta COVID-19 Study Group. Monk PD, et al. Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12. Lancet Respir Med. 2021. PMID: 33189161 Free PMC article. Clinical Trial.
Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis.
Jones MG, Andriotis OG, Roberts JJ, Lunn K, Tear VJ, Cao L, Ask K, Smart DE, Bonfanti A, Johnson P, Alzetani A, Conforti F, Doherty R, Lai CY, Johnson B, Bourdakos KN, Fletcher SV, Marshall BG, Jogai S, Brereton CJ, Chee SJ, Ottensmeier CH, Sime P, Gauldie J, Kolb M, Mahajan S, Fabre A, Bhaskar A, Jarolimek W, Richeldi L, O'Reilly KM, Monk PD, Thurner PJ, Davies DE. Jones MG, et al. Among authors: monk pd. Elife. 2018 Jul 3;7:e36354. doi: 10.7554/eLife.36354. Elife. 2018. PMID: 29966587 Free PMC article.
A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.
Cohen ES, Dobson CL, Käck H, Wang B, Sims DA, Lloyd CO, England E, Rees DG, Guo H, Karagiannis SN, O'Brien S, Persdotter S, Ekdahl H, Butler R, Keyes F, Oakley S, Carlsson M, Briend E, Wilkinson T, Anderson IK, Monk PD, von Wachenfeldt K, Eriksson PO, Gould HJ, Vaughan TJ, May RD. Cohen ES, et al. Among authors: monk pd. MAbs. 2014 May-Jun;6(3):756-64. doi: 10.4161/mabs.28394. Epub 2014 Feb 28. MAbs. 2014. PMID: 24583620 Free PMC article.
Experimental rhinovirus 16 infection in moderate asthmatics on inhaled corticosteroids.
Adura PT, Reed E, Macintyre J, Del Rosario A, Roberts J, Pestridge R, Beegan R, Boxall CB, Xiao C, Kebadze T, Aniscenko J, Cornelius V, Gern JE, Monk PD, Johnston SL, Djukanović R. Adura PT, et al. Among authors: monk pd. Eur Respir J. 2014 Apr;43(4):1186-9. doi: 10.1183/09031936.00141713. Epub 2013 Dec 5. Eur Respir J. 2014. PMID: 24311773 Free article. No abstract available.
Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma.
May RD, Monk PD, Cohen ES, Manuel D, Dempsey F, Davis NH, Dodd AJ, Corkill DJ, Woods J, Joberty-Candotti C, Conroy LA, Koentgen F, Martin EC, Wilson R, Brennan N, Powell J, Anderson IK. May RD, et al. Among authors: monk pd. Br J Pharmacol. 2012 May;166(1):177-93. doi: 10.1111/j.1476-5381.2011.01659.x. Br J Pharmacol. 2012. PMID: 21895629 Free PMC article.
11 results